PEPGEN (PEPG) ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Class Action Against PepGen and Encourages Investors to Contact the Firm
If you purchased or acquired securities in PepGen between March 7, 2024 and March 3, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
NEW YORK, Aug. 02, 2025 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against PepGen, Inc. ('PepGen' or the 'Company') (NASDAQ: PEPG) in the United States District Court for the Eastern District of New York on behalf of all persons and entities who purchased or otherwise acquired PepGen securities between March 7, 2024 and March 3, 2025, both dates inclusive (the 'Class Period'). Investors have until August 8, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Click here to participate in the action.
The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) PGN-EDO51 was less effective and safe than Defendants had led investors to believe; (ii) the CONNECT2 study was dangerous or otherwise deficient for purposes of U.S. Food and Drug Administration ('FDA') approval; (iii) as a result of all the foregoing, PepGen was likely to halt the CONNECT2 study, and PGN-EDO51's clinical, regulatory, and commercial prospects were overstated; and (iv) as a result, Defendants' public statements were materially false and misleading at all relevant times.
If you purchased or otherwise acquired PepGen shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com . Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.Brandon Walker, Esq.Marion Passmore, Esq.(212) 355-4648
[email protected]
www.bespc.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Axon (NASDAQ:AXON) Reports Upbeat Q2, Full-Year Outlook Slightly Exceeds Expectations
Self defense company AXON (NASDAQ:AXON) reported Q2 CY2025 results topping the market's revenue expectations , with sales up 32.8% year on year to $668.5 million. The company's full-year revenue guidance of $2.69 billion at the midpoint came in 1.2% above analysts' estimates. Its non-GAAP profit of $2.12 per share was 45% above analysts' consensus estimates. Is now the time to buy Axon? Find out in our full research report. Axon (AXON) Q2 CY2025 Highlights: Revenue: $668.5 million vs analyst estimates of $641 million (32.8% year-on-year growth, 4.3% beat) Adjusted EPS: $2.12 vs analyst estimates of $1.46 (45% beat) Adjusted EBITDA: $171.6 million vs analyst estimates of $160.7 million (25.7% margin, 6.8% beat) The company lifted its revenue guidance for the full year to $2.69 billion at the midpoint from $2.65 billion, a 1.5% increase EBITDA guidance for the full year is $675 million at the midpoint, in line with analyst expectations Operating Margin: -0.2%, down from 6.7% in the same quarter last year Free Cash Flow was -$114.7 million, down from $75.3 million in the same quarter last year Market Capitalization: $57.8 billion Company Overview Providing body cameras and tasers for first responders, AXON (NASDAQ:AXON) develops technology solutions and weapons products for military, law enforcement, and civilians. Revenue Growth A company's long-term performance is an indicator of its overall quality. Any business can have short-term success, but a top-tier one grows for years. Thankfully, Axon's 32.3% annualized revenue growth over the last five years was incredible. Its growth surpassed the average industrials company and shows its offerings resonate with customers, a great starting point for our analysis. We at StockStory place the most emphasis on long-term growth, but within industrials, a half-decade historical view may miss cycles, industry trends, or a company capitalizing on catalysts such as a new contract win or a successful product line. Axon's annualized revenue growth of 32.4% over the last two years aligns with its five-year trend, suggesting its demand was predictably strong. This quarter, Axon reported wonderful year-on-year revenue growth of 32.8%, and its $668.5 million of revenue exceeded Wall Street's estimates by 4.3%. Looking ahead, sell-side analysts expect revenue to grow 23.2% over the next 12 months, a deceleration versus the last two years. Despite the slowdown, this projection is healthy and indicates the market is baking in success for its products and services. Software is eating the world and there is virtually no industry left that has been untouched by it. That drives increasing demand for tools helping software developers do their jobs, whether it be monitoring critical cloud infrastructure, integrating audio and video functionality, or ensuring smooth content streaming. Click here to access a free report on our 3 favorite stocks to play this generational megatrend. Operating Margin Operating margin is an important measure of profitability as it shows the portion of revenue left after accounting for all core expenses – everything from the cost of goods sold to advertising and wages. It's also useful for comparing profitability across companies with different levels of debt and tax rates because it excludes interest and taxes. Axon was profitable over the last five years but held back by its large cost base. Its average operating margin of 1.8% was weak for an industrials business. On the plus side, Axon's operating margin rose by 17.7 percentage points over the last five years, as its sales growth gave it immense operating leverage. This quarter, Axon's breakeven margin was down 6.9 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Axon's EPS grew at an astounding 45.6% compounded annual growth rate over the last five years, higher than its 32.3% annualized revenue growth. This tells us the company became more profitable on a per-share basis as it expanded. Diving into Axon's quality of earnings can give us a better understanding of its performance. As we mentioned earlier, Axon's operating margin declined this quarter but expanded by 17.7 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its higher earnings; interest expenses and taxes can also affect EPS but don't tell us as much about a company's fundamentals. Like with revenue, we analyze EPS over a more recent period because it can provide insight into an emerging theme or development for the business. For Axon, its two-year annual EPS growth of 46.5% is similar to its five-year trend, implying strong and stable earnings power. In Q2, Axon reported adjusted EPS at $2.12, up from $1.20 in the same quarter last year. This print easily cleared analysts' estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects Axon's full-year EPS of $7.06 to shrink by 6.1%. Key Takeaways from Axon's Q2 Results We were impressed that Axon beat analysts' revenue and EBITDA expectations this quarter. Looking ahead, full-year revenue guidance was raised, showing a strong demand environment. Zooming out, we think this was a good print with some key areas of upside. The stock traded up 4.1% to $773 immediately following the results. Sure, Axon had a solid quarter, but if we look at the bigger picture, is this stock a buy? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free.
Yahoo
an hour ago
- Yahoo
Palantir Tops Q2, Raises Full-Year Forecast
Palantir (NASDAQ:PLTR) smashes Q2 forecasts with $0.16 Non-GAAP EPS and $1 billion revenue, then lifts full-year targets. The company delivered EPS of $0.16, beating by $0.02, and revenue jumped 47.5% to $1 billion, topping consensus by $60.53 million. Management projected Q3 revenue of $1.083 billion$1.087 billion versus $981.99 million expected and boosted full-year sales guidance to $4.142 billion$4.150 billion from a $3.90 billion consensus. Adjusted operating income is now seen at $1.912 billion$1.920 billion, while free cash flow is guided to $1.8 billion$2.0 billion. Warning! GuruFocus has detected 7 Warning Sign with MSFT. This beat-and-raise follows several quarters of accelerating growth, driven by strong demand across government and commercial segments. The higher guidance signals confidence in pipeline momentum and the company's ability to convert contracts into cash. It also underlines Palantir's push to sustain its blistering growth profile in an industry where peers often stumble on scale. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
MercadoLibre (NASDAQ:MELI) Beats Q2 Sales Targets But Stock Drops
Latin American e-commerce and fintech company MercadoLibre (NASDAQ:MELI) announced better-than-expected revenue in Q2 CY2025, with sales up 33.8% year on year to $6.79 billion. Its GAAP profit of $10.31 per share was 13.3% below analysts' consensus estimates. Is now the time to buy MercadoLibre? Find out in our full research report. MercadoLibre (MELI) Q2 CY2025 Highlights: Revenue: $6.79 billion vs analyst estimates of $6.54 billion (33.8% year-on-year growth, 3.9% beat) EPS (GAAP): $10.31 vs analyst expectations of $11.89 (13.3% miss) Adjusted EBITDA: $1.02 billion vs analyst estimates of $1.06 billion (15.1% margin, 3.2% miss) "This compression [in margin] was primarily driven growth investments..., and marketing spend also increased to support our free shipping and Mercado Pago campaigns. We are confident these are the right investments to make for the benefit of our users and our ecosystem" Operating Margin: 12.2%, down from 14.3% in the same quarter last year Free Cash Flow Margin: 38.7%, up from 12.8% in the previous quarter Unique Active Buyers: 71 million, up 14.4 million year on year Market Capitalization: $121.5 billion Company Overview Originally started as an online auction platform, MercadoLibre (NASDAQ:MELI) is a one-stop e-commerce marketplace and fintech platform in Latin America. Revenue Growth A company's long-term sales performance can indicate its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Luckily, MercadoLibre's sales grew at an incredible 39.7% compounded annual growth rate over the last three years. Its growth surpassed the average consumer internet company and shows its offerings resonate with customers, a great starting point for our analysis. This quarter, MercadoLibre reported wonderful year-on-year revenue growth of 33.8%, and its $6.79 billion of revenue exceeded Wall Street's estimates by 3.9%. Looking ahead, sell-side analysts expect revenue to grow 27.8% over the next 12 months, a deceleration versus the last three years. Still, this projection is eye-popping given its scale and implies the market is baking in success for its products and services. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories. Unique Active Buyers User Growth As an online marketplace, MercadoLibre generates revenue growth by increasing both the number of users on its platform and the average order size in dollars. Over the last two years, MercadoLibre's unique active buyers, a key performance metric for the company, increased by 20.8% annually to 71 million in the latest quarter. This growth rate is among the fastest of any consumer internet business and indicates its offerings have significant traction. In Q2, MercadoLibre added 14.4 million unique active buyers, leading to 25.4% year-on-year growth. The quarterly print was higher than its two-year result, suggesting its new initiatives are accelerating user growth. Revenue Per User Average revenue per user (ARPU) is a critical metric to track because it measures how much the company earns in transaction fees from each user. ARPU also gives us unique insights into a user's average order size and MercadoLibre's take rate, or "cut", on each order. MercadoLibre's ARPU growth has been exceptional over the last two years, averaging 15.4%. Its ability to increase monetization while growing its unique active buyers at an impressive rate reflects the strength of its platform, as its users are spending significantly more than last year. This quarter, MercadoLibre's ARPU clocked in at $95.63. It grew by 6.7% year on year, slower than its user growth. Key Takeaways from MercadoLibre's Q2 Results This compression [in margin] was primarily driven growth investments..., and marketing spend also increased to support our free shipping and Mercado Pago campaigns. We are confident these are the right investments to make for the benefit of our users and our ecosystem" Should you buy the stock or not? If you're making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it's free.
